Rheumatoid Arthritis
Conditions
Brief summary
To quantify the incremental cost of infections in patients treated with etanercept, adalimumab or infliximab versus abatacept.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age and older; * Have a diagnosis of of rheumatoid arthritis (ICD-9:714x.xx); * Have been enrolled for at least 6 months for the 6 months assessment and 12 months for the 12 months assessment; * are enrolled in a health plan between February 2006 and June 2009 * have claims indicating at least one use of either abatacept, etanercept, adalimumab or infliximab for at least 6 months for teh 6 months assessment and 12 months for the 12 months assessment
Exclusion criteria
* Patients not continuously eligible for health plan benefits for the same evaluation periods will be excluded * Patients who are on other biologics in the 6 and 12 month post-index period will be excluded (ex. those in the abatacept cohort will be excluded if they also have claims for etanercept in the 6 and 12 month post-index period). * Patients on biologics 6 months prior to the biologic index date will also be excluded * Patients with diagnosis for other non-RA conditions commonly treated with biologics (ex. Crohn's disease) during the 6 month pre-index period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incremental total and component (inpatient, outpatient and pharmacy) direct costs due to infection in patients treated with etanercept, adalimumab or infliximab versus abatacept | 6 months |
| Incremental total and component (inpatient, outpatient and pharmacy) direct costs due to infection in patients treated with etanercept, adalimumab or infliximab versus abatacept. | 1 year |
Outcome results
None listed